APA

Mitchell D., Bergendahl G., Ferguson W., Roberts W., Higgins T., Ashikaga T., DeSarno M., Kaplan J., Kraveka J., Eslin D., Werff A. V., Hanna G. K. & Sholler G. L. S. (20160425). A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. : Pediatric blood & cancer.

Chicago

Mitchell Deanna, Bergendahl Genevieve, Ferguson William, Roberts William, Higgins Timothy, Ashikaga Takamaru, DeSarno Mike, Kaplan Joel, Kraveka Jacqueline, Eslin Don, Werff Alyssa Vander, Hanna Gina K and Sholler Giselle L Saulnier. 20160425. A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. : Pediatric blood & cancer.

Harvard

Mitchell D., Bergendahl G., Ferguson W., Roberts W., Higgins T., Ashikaga T., DeSarno M., Kaplan J., Kraveka J., Eslin D., Werff A. V., Hanna G. K. and Sholler G. L. S. (20160425). A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. : Pediatric blood & cancer.

MLA

Mitchell Deanna, Bergendahl Genevieve, Ferguson William, Roberts William, Higgins Timothy, Ashikaga Takamaru, DeSarno Mike, Kaplan Joel, Kraveka Jacqueline, Eslin Don, Werff Alyssa Vander, Hanna Gina K and Sholler Giselle L Saulnier. A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. : Pediatric blood & cancer. 20160425.